Momenta And Mylan Make Strides On Aflibercept

Partners Are Aiming For Market Entry In 2023

 
• By Dean Rudge
  
Stairs
Momenta and Mylan are continuing to eye entry for a biosimilar to Eylea • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products